Multaq dronedarone regulatory update

EMA's CHMP recommended updating the label for Sanofi's atrial fibrillation (AF) drug Multaq dronedarone to include a contraindication against concomitant use with dabigatran. Multaq, a multichannel blocker with properties of antiarrhythmics in Vaughan-Williams classes I-IV, is approved in the EU to prevent recurrence of AF or to lower ventricular rate in patients with non-permanent AF. In the U.S., the drug is approved to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent AF or atrial flutter. ...